Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
SBLK heads into its November earnings with a striking internal contradiction: a cluster of senior insiders bought heavily at the end of September, only for directors to sell into the subsequent rally.
The insider picture dominates this week's story. On September 15, seven insiders bought a combined $6.4 million of stock at $28.27, a coordinated cluster that included the COO, co-CFO, Chief Strategy Officer, and two board members. Director Raffaele Zagari alone put in $1.7 million across two transactions. That buying spree pushed the 90-day net insider position to a net $5.3 million received, decisively in favour of the bulls. Since then, three directors have sold into the strength. Koert Erhardt sold 6,000 shares at $30.39 on October 5. Vrettou Eleni sold 3,500 at $32.12 in late September. Balakrishnan Mahesh sold 10,000 at $32.34. None of the sales were under 10b5-1 plans. The stock has since retreated to $29.70, down 3.4% on the week and 4.3% over the past month, meaning the sellers timed the top and the buyers are now sitting on modest paper losses.
Short positioning offers little drama here. At 2.35% of the free float, short interest is low by any standard and has edged up only 0.7% over the week. The borrow market is extremely loose, with availability running at more than 4,000%, meaning there are roughly 40 shares available to borrow for every one already lent out. Borrowing costs have also fallen sharply, down 86% week-on-week to 0.55% annualised, after a brief spike to 3.98% on September 30 that quickly faded. Options positioning is mildly more cautious than usual. The put/call ratio of 0.66 is about one standard deviation above its 20-day average of 0.56, a modest tilt toward protection rather than conviction directional hedging. Taken together, the lending market and options suggest this is not a heavily contested stock. Shorts are not pressing.
Ownership concentration is worth noting. Famatown Finance Limited, the vehicle associated with John Fredriksen, holds an 11.84% stake and filed a Schedule 13D, making it a registered activist position on the SEC's books. That filing was last updated in October 2025, so the disclosed level is over a year old. Per ORTEX's own disclosure, 13D/G stakes are event-driven around the 5% threshold and holders can fall below without refiling. Danaos Corporation holds a further 5.23% on a passive 13G. The two together account for more than 17% of shares, with Petros Pappas and family-connected holders adding another 7% or more. The register is tightly held, which partly explains why short interest remains low and the borrow pool is so deep relative to what is actually being shorted.
The Street's most recent view comes from Jefferies, which raised its target to $31 in late May and holds a Buy rating. At $29.70, that leaves implied upside of roughly 4% to the Jefferies target and about 9% to the mean analyst target of $32.38. The bull case rests on Q4 booking momentum described as the strongest since early 2024 and cash reserves of $452.5 million. Bears point to Q3 adjusted EPS of $0.28 missing the $0.32 consensus and Kamsarmax rates that have softened 15% from their July 2025 peak. The EV/EBITDA multiple of 6.4x and P/E of 8.2x keep absolute valuation undemanding, but both have drifted lower over the past month alongside the stock. The ORTEX earnings-surprise factor ranks at the 84th percentile, suggesting the company has a track record of beating. Recent prints bear that out only partially: the August 2026 result produced a 3.4% one-day gain, while the May print was flat to slightly negative.
Across the peer group, dry bulk names moved in sympathy this week. GNK fell 4.7% on the day and 4.2% on the week. SB dropped 3.3% Friday and 3.2% on the week. SHIP was off 3.0% and 4.0% respectively. DSX held up better, losing only 1.4% on the week. The sector-wide weakness makes SBLK's own decline look more like a market move than stock-specific pressure, though the insider selling activity adds a layer of company-specific caution.
With Q3 results due November 18, the question now is whether the September buyer cluster was genuinely early and right, or whether the directors who sold at $32 had a clearer read on near-term rate dynamics than the executives who bought at $28.
See the live data behind this article on ORTEX.
Open SBLK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
